The laboratory on top of the world
Mocon installs permeation units in testing lab in Tibet, nearly 3,500m above sea level
Located at 3,490m above sea level, this is Mocon’s highest altitude installation. The units will be used to measure package permeation for traditional Tibetan herbal remedies and conventional pharmaceuticals.
The Lhasa laboratory has installed a Mocon Ox-Tran 2/21 ML and a Permatran-W Model 3/33 MG Plus unit. Both test permeation of either flat materials or finished packages/devices such as vials, pouches, bottles, blister cavities and syringes. However, in Lhasa, they will be used primarily for high barrier testing of packaging structures with either aluminum foil or metallised layers.
The Ox-Tran 2/21 system also features barometric pressure compensation, which ‘normalises’ the test results to sea level to ensure uniform test results worldwide, regardless of altitude or weather conditions. It also uses a patented Coulox coulometric sensor to detect oxygen transmission. Mocon says it provides parts-per-billion sensitivity even in the presence of water vapour.
The Permatran-W Model MG 3/33 Plus offers automatic relative humidity (RH) capability. Its software interface enables the instrument to achieve accurate and precise relative humidity conditions simply and quickly.
The installation is part of an order received from China’s State Food & Drug Administration (SFDA) to supply 20 provincial pharmaceutical testing centres with oxygen and water vapour permeation units.
Mocon established an office, laboratory and service centre in Shanghai in 2007 to provide permeation technology for growing economies in the Asia-Pacific region.
Mocon’s agent, Danbell Equipment Company, Beijing, also supports the company in the region.
You may also like
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Manufacturing
Lonza appoints Hans Trees as Global Head of Communications
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing
AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn
AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn